Featured Story

RNAi specialist Arrowhead reports loss of $58.7M in FY 2014

Arrowhead Research reported a net loss of $58.7 million in fiscal year 2014, up from $31.7 million in FY 2013.

Singapore team combines cancer drugs, diagnostics in one biomarker nanoparticle

Combining diagnostics and drug delivery is an ideal progression to improve the effectiveness and speed of treatment and a way to make drugs "smarter." To make one of these two-in-one systems, Singapore-based researchers developed a new biomarker that lights up to locate tumors and releases cancer drugs at the same time.

Pfizer-Merck KGaA collaboration could benefit other oncology players with novel delivery tech

Pfizer's partnership with German counterpart Merck KGaA for $850 million upfront, plus as much as $2 billion in milestones, improves the prospects of PD-L1 and PD-1 checkpoint inhibitors in the oncology space, to the excitement of developers of combination therapies to the class of medicines, which feature both biological and mechanical mechanisms.

'Hybrid' delivery vehicle gives DNA vaccines new potential

Researchers have developed a delivery vehicle that could help push DNA vaccines--those based on a small part of a microbe's genes--into a more prominent position and possibly into the market down the road.

Survey raises the question: Do patients really know how to use drug delivery devices?

Patients are overconfident in their ability to operate drug delivery medical devices and may not realize that they are using them incorrectly, a comprehensive survey by the U.K.'s Team Consulting shows.